Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

4.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4
Open 4.760
Bid (Size) 4.760 (4)
Ask (Size) 4.850 (8)
Prev. Close 4.760
Today's Range 4.760 - 4.760
52wk Range 1.535 - 6.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
Via Benzinga
Exposures Product Safety
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
From 2seventy bio, Inc.
Via Business Wire

Performance

YTD
+16.10%
+16.10%
1 Month
+4.16%
+4.16%
3 Month
+26.60%
+26.60%
6 Month
-11.03%
-11.03%
1 Year
+33.71%
+33.71%

More News

Read More
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
From 2seventy bio
Via Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
From 2seventy bio, Inc.
Via Business Wire
3 Hidden Stock Gems That Wall Street Is Overlooking
Via InvestorPlace
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Via Benzinga
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
From 2seventy bio, Inc.
Via Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Via Benzinga
Exposures Product Safety
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
From 2seventy bio, Inc.
Via Business Wire
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.